Emerging MedTech Sebia is recognized as a Top Emerging MedTech Company in India for 2025, signaling strong growth potential and favorable market reception in the Indian diagnostics sector, which presents partnership and channel opportunities for expanding sales.

India Collaboration Recent partnerships and awards in India, including the BioSpectrum recognition and Synergies with local diagnostics players, indicate a receptive market for Sebia’s diagnostics solutions and potential for co-development or distribution deals.

Expanded US Portfolio Sebia expanded hemoglobinopathy testing in the United States with an integrated, workflow-friendly solution, suggesting demand for automation and traceability enhancements that can be cross-sold to labs seeking end-to-end solutions.

Multiple Myeloma Focus Ongoing activity around multiple myeloma diagnostics and MRD testing signals a continued opportunity for sales of IVD antibodies, assays, and monitoring tests to hematology labs and oncology centers.

Global Lab Automation With a product focus on automation of autoimmunity and infectious disease tests and a tech stack supporting cloud, data analytics, and workflow integration, there is potential to upsell digital lab IT integrations, ELISA/immunoassay automation, and analytics-enabled monitoring to modern labs.